203 published test results across 45 vendors · latest: 12 Oct 2026
| # | Vendor | Tests | Price/mg | Score |
|---|---|---|---|---|
| 1 | SShanghai Baoju Unverified | 5 | — | 69 |
| 2 | MMT Meipept Unverified | 3 | — | 64 |
| 3 | LLSPL Unverified | 3 | $2.00 | 63 |
| 4 | ZZLZ Peptide Unverified | 3 | — | 62 |
| 5 | HHXNet Unverified | 15 | $1.76 | 62 |
| 6 | YYiwu Aozuo Trading Co Unverified | 7 | — | 62 |
| 7 | HHaikou Mingheng Biotechnology Unverified | 7 | $5.25 | 62 |
| 8 | IInno Peptides Unverified | 2 | $2.16 | 62 |
| 9 | HHK Peptides Unverified | 11 | $2.30 | 60 |
| 10 | NNantong Guangyuan Chemical GYC Unverified | 4 | $7.20 | 60 |
Computed from publicly published third-party results. How scoring works · every listing is free and un-buyable. Vendors marked Unverified appear for their published results but are left out of the vendor rankings.
Cagrilintide is Novo Nordisk’s long-acting amylin analog, best known as the other half of CagriSema, the combination with semaglutide that posted a 22.7% mean weight reduction at 68 weeks in the phase 3 REDEFINE 1 trial. That number made headlines for missing Novo’s own 25% target, which says something about where expectations in this drug class have gone.
Nobody runs cagrilintide alone; the gray market buys it to pair with semaglutide, imitating CagriSema years ahead of any approval. The record reflects a compound in active demand: 142 published tests across 24 vendors, with leader scores from 62 to 68 and dates running through July 2026. Middling scores on modest per-vendor records (five to fifteen tests each) is the pattern here, so no seller has separated from the pack yet.
Published pricing among scored vendors runs $1.76 to $5.25 per milligram as of September 2026, a three-fold spread with no matching gap in scores. One caution specific to this compound: because demand is stack-driven, some sellers push cagri/sema blend vials. A blend COA has to verify both peptides and both quantities, which doubles the ways a label can be wrong. Single-compound vials with separate certificates are the cleaner data trail.
No. It exists in trials only as part of CagriSema, which remains under regulatory review. Everything sold today is research-chemical production.
Verifiability. Two single-compound vials mean two independent certificates against two labels. A blend vial is one certificate that has to get twice as much right.
The newest published result is from July 2026 and most leaders tested inside 2026, though one top-five entry dates to March. The last-tested column carries that detail per vendor.
Nothing on this page is medical advice; compounds shown are sold for research purposes only. Data is aggregated from publicly published third-party results and traces to its source.